Paper Details

  1. Home
  2. Paper Details

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

Author: BerckmansCindy, De SmedtGoedele, HoetelmansRichard M W, KakudaThomas N, PeetersMonika, Schöller-GyüreMonika, WoodfallBrian

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

No clinically relevant differences were observed between patients with mild or moderate hepatic impairment and healthy matched subjects with regard to the pharmacokinetics of etravirine. No dose adjustment of etravirine appears to be necessary in patients with mild or moderate hepatic impairment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against both wild-type HIV and viruses harboring NNRTI resistance. Etravirine is mainly eliminated via the hepatobiliary route. OBJECTIVES: This study in HIV- patients with mild or moderate hepatic impa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2010.02.013

データ提供：米国国立医学図書館（NLM）

Exploring the Effects of Hepatic Impairment on Etravirine Pharmacokinetics

In the vast desert of HIV research, understanding the impact of hepatic impairment on drug pharmacokinetics is essential for optimizing treatment strategies. This research investigates the effects of mild and moderate hepatic impairment on the steady-state pharmacokinetics of etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in HIV treatment. The study, involving HIV-negative patients and healthy controls, reveals that etravirine pharmacokinetics are not significantly affected by mild or moderate hepatic impairment. These findings provide crucial insights for clinicians, enabling them to confidently prescribe etravirine to patients with hepatic impairment without requiring dose adjustments.

Etravirine: A Safe and Effective Treatment Option for Patients with Hepatic Impairment

This research offers a clear path for clinicians managing HIV-infected patients with hepatic impairment. The study demonstrates that etravirine, a vital NNRTI, can be safely and effectively prescribed without dose adjustments, even in patients with mild or moderate hepatic impairment. This finding is a valuable tool for improving treatment outcomes and ensuring optimal patient care.

Navigating the Terrain of HIV Treatment

While this study provides encouraging results, it's essential to monitor patients for any potential side effects and adjust treatment strategies accordingly. Further research is needed to fully understand the long-term effects of etravirine in patients with hepatic impairment and optimize treatment protocols.

Dr. Camel's Conclusion

This research provides a beacon of hope for individuals living with HIV and hepatic impairment, demonstrating that etravirine can be safely and effectively used without dose adjustments. This discovery represents a significant step forward in optimizing HIV treatment strategies for patients with compromised liver function, paving the way for improved outcomes and quality of life.
Date :
  1. Date Completed 2010-05-28
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

20206790

DOI: Digital Object Identifier

10.1016/j.clinthera.2010.02.013

Related Literature

Article Analysis
・Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.